600557 Jiangsu Kanion Pharmaceutical
- 14.48
- +0.31+2.19%
Jiangsu Kanion Pharmaceutical News
Kangyuan Pharmaceutical: Announcement of the progress of Jiangsu Kangyuan Pharmaceutical Co., Ltd. on the repurchase of the company\'s shares through centralized bidding transactions
Announcement of Jiangsu Kangyuan Pharmaceutical Co., Ltd. on completing the registration of industrial and commercial changes and issuing a business license
Announcement of Jiangsu Kangyuan Pharmaceutical Co., Ltd. on receiving the KYS202004A injection clinical trial approval notice
Rules for the Board of Directors Meeting of Jiangsu Kanion Pharmaceutical Co., Ltd. (Revised on August 12, 2024)
Jiangsu Kanion Pharmaceutical Co., Ltd. Company Charter (revised on August 12, 2024)
Legal opinion of Jiangsu Century Tongren Law Firm on the first interim shareholders' meeting of Jiangsu Kanion Pharmaceutical Co., Ltd. in 2024.
Announcement of the resolutions of the first extraordinary shareholders' meeting of Jiangsu Kanion Pharmaceutical Co., Ltd. in 2024.
Jiangsu Kanion Pharmaceutical: Announcement of Jiangsu Kanion Pharmaceutical Co., Ltd.'s progress on repurchasing the company's shares through centralized bidding trading to achieve a percentage of 1%.
Materials for the first interim shareholders' meeting of Jiangsu Kanion Pharmaceutical Co., Ltd in 2024.
Notice on convening the first extraordinary general meeting of shareholders of Jiangsu Kanion Pharmaceutical Co., Ltd. in 2024.
Announcement on the election of non-independent directors for the eighth board of directors of Jiangsu Kanion Pharmaceutical Co., Ltd.
Announcement from Jiangsu Kanion Pharmaceutical Co., Ltd. regarding signing a framework agreement for construction projects with its wholly-owned subsidiary and related transactions.
Announcement by Jiangsu Kanion Pharmaceutical Co., Ltd. Regarding Resignation of Senior Management Personnel.
Announcement of Jiangsu Kanion Pharmaceutical Co., Ltd. on the Appointment of Board of Directors' Secretary.
Announcement of Jiangsu Kangyuan Pharmaceutical Co., Ltd. on receiving the approval notice for the clinical trial of Shichimi Fatty Liver Granules
Announcement of Jiangsu Kangyuan Pharmaceutical Co., Ltd. on receiving a notice of approval for the clinical trial of Qiangqin granules
Announcement of Jiangsu Kangyuan Pharmaceutical Co., Ltd. on the resignation of the director and secretary of the board of directors
Announcement of Jiangsu Kangyuan Pharmaceutical Co., Ltd. on the appointment of a deputy general manager
Announcement of Jiangsu Kangyuan Pharmaceutical Co., Ltd. on changing the registered capital, increasing the scope of business and amending the “Articles of Association”
Jiangsu Kangyuan Pharmaceutical Co., Ltd. Independent Director Annual Report Work System (Revised in April 2024)
Analysis
Price Target
No Data
No Data